Octreotide LAR Depot
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Gastrointestinal Bleeding
Conditions
Gastrointestinal Bleeding
Trial Timeline
Feb 1, 2013 → Oct 1, 2014
NCT ID
NCT01707225About Octreotide LAR Depot
Octreotide LAR Depot is a phase 1 stage product being developed by Novartis for Gastrointestinal Bleeding. The current trial status is completed. This product is registered under clinical trial identifier NCT01707225. Target conditions include Gastrointestinal Bleeding.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01707225 | Phase 1 | Completed |
Competing Products
20 competing products in Gastrointestinal Bleeding